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Editorial on the Research Topic
Cytotoxic CD4+ T Cells in Viral Infections
Since the 1970s, recurrent observations have been made that CD4+ T cells are not mere helpers 
but can also have cytotoxic activity, as originally described in murine allogeneic responses and then 
in human memory CD4 T cell recall responses to viral antigens. Pathogens that chronically infect 
cells of the human immune system, including some of the world’s most prevalent persistent infec-
tions, such as EBV, CMV, HIV-1, TB, HHV-8, and HTLV-1, are usually thought of as controlled by 
CD8 CTL and neutralizing antibodies, but these pathogens have evolved mechanisms to avoid this 
control, especially downregulation of HLA Class I antigen presentation. However, the target cells 
of these pathogens constitutively express HLA Class II and therefore represent a potentially direct 
focus of CD4 effector cells. In fact, a recent study showed that even CD8 T cells may use HLA Class 
II restriction to control CMV infection in a rhesus macaque model (1).
In vivo murine models have recently confirmed that cytotoxic CD4+ T cells (CD4 CTL) are a 
unique CD4 T cell subset with cytolytic capabilities. In the context of viral infections such as West 
Nile virus (2), influenza (3), and Friend virus (4), it has been demonstrated that cytotoxic CD4+ 
T cells are readily detectable ex vivo and can contribute to viral containment even in the absence of 
antigen-specific CD8+ T cell or B cell responses. Moreover, it has also been shown that cytotoxic 
CD4+ T cells may play an important protective role in chronic viral infections, as evidenced by their 
control of viral replication in EBV and CMV infection. CD4+ T cells from HIV-infected patients 
have been shown to express large quantities of cytolytic effector molecules such as perforin and 
granzymes, immediately ex vivo, and HIV-specific CD4+ T cell clones and cell lines can readily 
mediate target cell lysis and viral inhibition in vitro (5). Distinct phenotype, lineage commitment, and 
function of these cytotoxic CD4+ T cells in viral infections are currently under intense investigation.
Based on studies on virus-specific T cells in humans, it was postulated that effector memory T cells 
differentiate in a linear path from CD28+CD27+ (early-differentiated) to CD28+CD27− (interme-
diate-differentiated) to CD28−CD27− (late-differentiated) (6). Presence of CD4+CD28negative or 
null T cells has been extensively observed in inflammation and auto-immunity for the past 20 years. 
They have distinct regulatory pathways during activation and have been postulated to be replication 
senescent (7). Chronic CMV infection drives the CD4+CD28− phenotype, and their expansion 
is associated with cardiovascular disease, rheumatoid arthritis, and other autoimmune conditions 
(Broadley et al.). CD4+CD28− cells produce large amounts of IFNγ and TNFα, express cytotoxic 
granule markers granzyme B and perforin, and exert cytolytic activity demonstrated by in vitro and 
in vivo models (Muraro et al.). Virus-driven expansion of these cytotoxic cells may cause complica-
tions to autoimmunity, where they play an effector role that mediates inflammation. However, cur-
rent studies demonstrate that these very same cells may have a protective role against viral infections. 
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They have presumably evolved to offer protections against viral 
infections and cancer (8) but can also potentially represent a 
T cell subset that drives inflammation and fibrosis.
The role of CD4 CTL on the containment of viral replication 
has often been overshadowed by the presence of cytotoxic CD8+ 
T cells that outnumber them. CD8+ T cells have long been rec-
ognized as the major contributor of control in acute and chronic 
viral infections; however, their role is now not as substantial as 
previously thought. Incomplete control and viral immune escape 
mechanisms have been described together with the ability of 
some viruses to downregulate MHC class I expression, which 
suggests that an alternate cytotoxic pathway may contribute to 
viral control. CD4 CTL that recognizes viral epitopes via MHC 
class II may act in concert with CD8 CTL to further strengthen 
viral control (Muraro et al.). CD4 CTL has been shown to play a 
pivotal role in the containment of viral replication in influenza, 
EBV, and CMV infections (Juno et al.). Recent studies on HIV-1, 
dengue virus (Tian et al.), and HPV have shown that CD4 CTL 
cells are activated and highly cytotoxic and may prevent disease 
progression.
Markers specific for CD4 CTL have not been identified. 
Whether CD4 CTL composed of a single subset or multiple sub-
types requires further examination. Innate activation markers, 
such as NKG2D and KLRG1, have been identified on their sur-
face. Recently, Takeuchi and Saito identified the class I-restricted 
T cell-associated molecule (CRTAM) as a marker of CD4 CTL 
(9). CRTAM is an early activation marker of NK and CD8+ 
T cells. CRTAM is expressed transiently on early-activated CD4+ 
T cells that have cytotoxic activity. However, due to the kinetics of 
CRTAM expression, its use as an in vivo CD4 CTL marker is lim-
ited. Mattoo et al. identified SLAMF7 as a marker of CD4 CTL in 
IgG4-related disease; a chronic inflammatory syndrome that can 
affect any organ system in the body and manifests as storiform 
fibrosis, obliterative phlebitis, tumefactive lesions, and high levels 
of IgG4-secreting plasma cells in inflamed tissues. CD4+ T cells 
that express SLAMF7 displayed a cytotoxic phenotype with the 
expression of Granzyme A, IL-1β, and TGF-β1 and were clon-
ally expanded in inflamed IgG4-RD tissue sites (10). SLAMF7 
represents a marker that distinguishes CD4+CTLs from all other 
CD4+ T cell subsets.
Limited studies on the differentiation and proliferation of 
CD4+CTLs have been reported. CD4 CTLs can apparently 
develop from multiple T helper subsets, with Th1-like cells 
representing the majority of CD4 CTL expressing IFNγ, TNFα, 
and/or IL-2 (5, 11), but also CD40L (12). CD4 CTL differentia-
tion and function, such as other T helper subsets, require essential 
transcription factors that orchestrate transcription of key genes. 
Tbet and Eomes are important CD8 transcription factors that 
have been postulated to regulate CD4 CTL function, and the level 
of expression of Tbet and Eomes may depend on their matura-
tion stage (Brown et al.). Recently, Oja et al. identified that the 
transcription factor Hobit (Homologo of Blimp-1 in T  cells) 
was specifically upregulated in CD45RA+ effector CD8+ T cells 
in hCMV infection. Hobit expression was further identified in 
CD4+ T cells, and Hobit+ CD4+ T cells had a cytotoxic profile 
similar to Hobit+ CD8+ T cells, including the expression of Tbet 
and fractalkine receptor CX3CR1 (Oja et al.). It is still unclear 
however, what signals are required for the upregulation of Hobit 
after hCMV infection. Tbet is postulated to be responsible for the 
maintenance of Hobit after viral clearance, although it has not 
been proven. Whether Hobit is also upregulated in other viral 
infections and its role in CD4 CTL function warrants further 
examination.
CD4 CTL cells are long-lived and have been shown in many 
viral infections to be effective in the elimination of infected target 
cells. With these properties, CD4 CTL cells are thus a potential 
candidate for adoptive transfer strategies for cellular treatment 
of chronic viral infections and virus-driven tumors. However, 
several hurdles need to be overcome to fully utilize these cells 
for therapy. Identification of lineage markers and transcription 
factors need to be defined, as well as their expansion and mainte-
nance (essential homeostatic cytokines) needs to be determined. 
Emerging research on this subset will expand our knowledge of 
the complex T helper response and will shed light on another 
effector cell type that has a killing potential.
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